Human cytomegalovirus (HCMV) is a significant cause of morbidity and mortality in immunocompromised populations (Alford & Britt, 1993) . There are currently three nucleoside analogues available in the USA as drugs for the treatment of HCMV infection: ganciclovir (GCV), foscarnet and cidofovir (Crumpacker, 1996; Hitchcock et al., 1996 , Chrisp & Clissold, 1991 . In addition, the antisense oligonucleotide fomivirsen has been approved for direct treatment of HCMV retinitis (Mulamba et al., 1998; Perry & Balfour, 1999) . However, use of these drugs is limited by low oral bioavailability, in vivo toxicity, inconvenient administration methods and the development of resistance (Field & Biron, 1994) . These deficiencies demonstrate the need for new compounds to treat HCMV infections.
We have reported that 2,5,6-trichloro-(1-β-D-ribofuranosyl)benzimidazole (TCRB) and the 2-bromo analogue, BDCRB, are potent and selective inhibitors of HCMV (Townsend et al., 1995) . The benzimidazole ribonucleosides have a unique mode of action in that there is no effect on the synthesis of viral DNA . Instead, these compounds inhibit the cleavage of high molecular weight, concatemeric viral DNA to monomeric genome-length units .
Benzimidazole ribonucleoside-resistant mutants of HCMV have been independently isolated from HCMV strains AD169 and Towne. In studies with AD169, 10-fold resistance resulted from single mutations in the UL89 open reading frame (ORF) (Asp344Glu or Ala355Thr), and 30fold resistance resulted from a combination of both the position 344 and 355 mutations in UL89 . In studies with Towne, a resistant mutant was identified (isolate C4) that was ~30-fold resistant to the benzimidazole ribonucleosides. This isolate had mutations in both the UL89 and UL56 ORFs (UL89, Asp344Glu and UL56, Gln204Arg) (Krosky et al., 1998) . Either of these mutations alone caused 10-fold resistance, but both were required for the higher level of resistance. The HSV-1 homologues of UL89 and UL56 (UL15 and UL28, respectively) code for essential proteins that are required for viral DNA cleavage and packaging (Poon & Roizman, 1993; Yu et al., 1997; Baines et al., 1994; Addison et al., 1990; Pancake et al., 1983; Tengelsen et al., 1993) . Thus, mapping of benzimidazole ribonucleoside resistance to packaging genes is consistent with the observed inhibition The AD169 strain of human cytomegalovirus was approximately twofold more sensitive to polyhalogenated benzimidazole ribonucleosides than Towne strain. Sequence differences between the two strains have been identified in genes UL51, UL52, UL56, UL77, UL89 and UL104. Because these genes are involved in cleavage and packaging of viral DNA and the benzimidazole ribonucleosides inhibit this process, these sequence differences may be involved in the difference in drug sensitivity.
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of viral DNA maturation.
An evaluation of data from a number of antiviral susceptibility assays in our laboratory suggested HCMV strain AD169 was more sensitive to the benzimidazole ribonucleosides than HCMV strain Towne. The assays were performed as previously described (Townsend et al., 1995) . Briefly, HFF cells in 24-well cluster dishes were infected with approximately 100 p.f.u. of HCMV per well. Following virus adsorption, compounds dissolved in growth medium were added to duplicate wells at four to eight selected concentrations. After incubation at 37°C for 10 days, cell monolayers were stained with crystal violet, and plaques were enumerated at 40-fold magnification.
Drug effects were calculated as a percentage of reduction in the number of plaques observed in the presence of each drug concentration compared to the number observed in the absence of drug. A rigorous comparison of 50% inhibitory concentrations (IC 50 ) from two to 20 independent plaque reduction assays revealed an approximately twofold greater sensitivity of strain AD169 to both TCRB (P<0.043) and BDCRB (P<0.028) ( Table 1) . As a control, the susceptibility of the two strains to ganciclovir was compared and it was identical (P=0.97). Thus the differences in susceptibility appear to be unique to benzimidazole nucleosides. In related studies, we also noted a two-to sixfold greater sensitivity of strain AD169 to α-lyxosyl and β-erythrosyl analogues of TCRB and BDCRB (Migawa et al., 1998; Gudmundsson et al., 2000) .
In a broader examination of HCMV resistance to the benzimidazoles, differences between HCMV strains AD169 and Towne were explored by comparison of the sequences of six genes known to be involved in viral DNA processing and packaging. UL51, UL52, UL56, UL77, UL89 and UL104 ORFs were sequenced from Towne as described by us (Krosky et al., 1998) . Briefly, viral stocks (~10 6 p.f.u./ml) were lysed in an equal volume of 1× PCR buffer (Perkin Elmer, Foster City, Calif., USA), 0.05% NP-40 and 0.05% Tween 20. These were digested with proteinase K (100 µg/ml) and the specific viral genes were Chee et al. (1990) . The UL89 ORF from strain AD169 also was sequenced, and was identical to the sequence published by Chee et al. (1990) . All six genes had at least one non-coding and one coding change between the two strains of HCMV (Table 2 ). The least changes were found in UL51; the most dramatic differences were in the UL77 ORF, where Towne strain encoded a protein that was seven amino acids shorter than the protein encoded by AD169.
It is most likely that the differences between strains AD169 and Towne that resulted in altered sensitivity to the benzimidazole ribonucleosides are located in either the UL89 or the UL56 ORFs because the products of both of these genes have been linked to the activity of these compounds (Krosky et al., 1998; Underwood et al., 1998) . All of the coding changes in the UL56 ORF resulted in the conservative substitution of an alanine in Towne for a valine in AD169, and thus are less likely to be the cause of the difference in drug sensitivity. The changes in the UL89 ORF were also rather conservative but are more likely to be related to drug sensitivity. Of particular note is the difference at position 1107 of exon 2 resulting in a change from an aspartic acid in AD169 to a glutamic acid in Towne at amino acid 666. A similar change of aspartic acid to glutamic acid at amino acid 344 results in 10-fold resistance to the benzimidazole ribonucleosides . The differences in benzimidazole sensitivity also could be related to the difference at position 145 of exon 2, which resulted in a serine to alanine change at amino acid 345. This is next to the mutation site at amino acid 344, which renders benzimidazole resistance .
In summary, HCMV strain AD169 was more sensitive to the benzimidazole ribonucleosides than was strain Towne. The benzimidazole ribonucleosides inhibit viral DNA cleavage and processing, and this strain difference in sensitivity may be a result of one or more of multiple sequence differences in the six genes essential for viral DNA maturation.
